Treatment of tardive dyskinesia: A systematic review (1997-2011)
Eur. j. psychiatry
; 27(3): 160-173, jul.-sept. 2013. ilus, tab
Artigo
em Inglês
| IBECS
| ID: ibc-117381
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
Background and Objectives:
Tardive dyskinesia (TD) is a frequent and incapacitating side effect of first-generation antipsychotics. Although second-generation antipsychotics (SGAs) seem to be associated with a decreased risk of TD, it remains a severe, unresolved iatrogenic condition. Moreover, there is no commonly accepted effective treatment for TD. We conducted a systematic review of the literature to assess evidence regarding the effectiveness of different therapeutic interventions for TD.Methods:
We performed a systematic review focussing exclusively on randomised controlled trials (RCTs). We searched the MEDLINE database (1997 to 2011) using the keyword "tardive dyskinesia" within the "title" search field. Twenty-six RCTs were included. Based on the evidence from RCTs, we built a decision tree that healthcare professionals can use to choose an effective therapeutic intervention for TD.Results:
Four therapeutic interventions were found to be effective in TD (vitamin B6, ginkgo biloba, branched-chain amino acids, and piracetam).Conclusions:
Patients with TD could benefit from the therapeutic interventions supported by the data accumulated from RCTs (AU)
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Antipsicóticos
/
Discinesia Induzida por Medicamentos
/
Transtornos Mentais
Tipo de estudo:
Ensaio clínico controlado
/
Estudo diagnóstico
/
Estudo de etiologia
/
Estudo prognóstico
/
Fatores de risco
/
Revisão sistemática
Limite:
Humanos
Idioma:
Inglês
Revista:
Eur. j. psychiatry
Ano de publicação:
2013
Tipo de documento:
Artigo
Instituição/País de afiliação:
CHRU de Tours/France